Kodiak Sciences Inc - KOD STOCK NEWS

Kodiak Sciences Inc. (Nasdaq: KOD) has announced a public offering of 5,193,237 shares of common stock at $108.00 per share, aiming to raise approximately $560.9 million before expenses. The offering is set to close on or around November 20, 2020, pending customary conditions. An option for underwriters to purchase an additional 778,985 shares is also included. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are the lead managers for this offering, which follows an effective shelf registration statement with the SEC.

Kodiak Sciences Inc. (Nasdaq: KOD) has announced a proposed underwritten public offering of $400 million of its common stock, with underwriters granted a 30-day option to purchase an additional $60 million. The offering is subject to market conditions and may not complete as planned. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are the joint book-running managers. The shares are being offered under a previously filed shelf registration statement that became effective on November 16, 2020.

Kodiak Sciences Inc. (Nasdaq: KOD) announced the completion of patient recruitment for its DAZZLE pivotal study of KSI-301, an anti-VEGF therapy targeting wet age-related macular degeneration. The study exceeded its goal of 550 treatment-naïve patients, despite COVID-19 challenges. Top-line data is expected in early 2022. KSI-301 aims to offer a less frequent treatment regimen, potentially improving vision outcomes. Additional studies for diabetic macular edema and retinal vein occlusion are also progressing, supporting Kodiak's development objectives in retinal disease therapies.

Kodiak Sciences Inc. (Nasdaq: KOD) announced management presentations at two virtual investor conferences: the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 11:20 a.m. PT, and the Evercore ISI HealthCONx Conference on December 3, 2020, at 8:20 a.m. PT. A live webcast will be available on Kodiak's website, along with replays shortly after each event. Kodiak focuses on developing therapeutics for retinal diseases, highlighted by its lead candidate, KSI-301, targeting age-related macular degeneration and diabetic eye diseases.

Kodiak Sciences (Nasdaq: KOD) presented clinical data for KSI-301 at the AAO 2020 Virtual Annual Meeting, emphasizing its long-term efficacy and safety in treating diabetic macular edema (DME). The presentation, led by Dr. Arshad M Khanani, highlighted the promising durability and efficacy of KSI-301 compared to current anti-VEGF treatments. The ongoing Phase 3 GLEAM and GLIMMER studies aim to enroll approximately 450 patients each to assess KSI-301's impact on vision correction over two years. KSI-301 is positioned to address the significant treatment burden in diabetic eye diseases.

Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q3 2020 results, highlighting significant progress in clinical trials for KSI-301, a potential treatment for retinal diseases. The company completed U.S. enrollment for the DAZZLE study, with 545 out of 550 patients enrolled, expected to conclude by year-end 2020. Kodiak also initiated two Phase 3 studies in Diabetic Macular Edema and one in Retinal Vein Occlusion, aiming for a BLA submission in 2022. Despite a net loss of $36.1 million, Kodiak maintains a solid cash position of $380.5 million, projected to fund operations into 2022.

Kodiak Sciences Inc. (Nasdaq: KOD) announced on Oct. 5, 2020, that it has treated the first patients in pivotal Phase 3 studies for KSI-301, an anti-VEGF therapy targeting diabetic macular edema (DME) and retinal vein occlusion (RVO). The studies, GLEAM and GLIMMER, focus on treatment-naïve DME patients, while BEACON targets RVO patients. The ongoing DAZZLE study for wet AMD has completed U.S. recruitment. Initial Phase 1b results indicate that KSI-301 demonstrates significant durability with high treatment-free intervals. Kodiak aims to submit a BLA for KSI-301 by 2022.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical firm focused on retinal diseases, will present at two virtual investor conferences: the Citi 15th Annual BioPharma Conference on September 10 at 9:35 a.m. PT and the Morgan Stanley 18th Annual Global Healthcare Conference on September 17 at 10:15 a.m. PT. Webcasts of these presentations will be available on Kodiak's website, along with a limited-time replay option. Kodiak is advancing therapies aimed at preventing blindness caused by retinal conditions using its proprietary ABC Platform™.

Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q2 2020 results, highlighting significant advancements in their KSI-301 program targeting retinal diseases. CEO Victor Perlroth noted robust enrollment in the DAZZLE study for wet AMD, with 375 patients enrolled as of July 30, 2020. The company has a strong cash position of $417.1 million, but reported a net loss of $26 million. Increased R&D expenses of $20.6 million reflect ongoing clinical development. Kodiak remains on track for pivotal study initiations in 2020 and aims for a BLA submission in 2022.